These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Selective cyclooxygenase-2 inhibitors and non-small cell lung cancer. Gridelli C; Maione P; Airoma G; Rossi A Curr Med Chem; 2002 Nov; 9(21):1851-8. PubMed ID: 12369871 [TBL] [Abstract][Full Text] [Related]
4. HER-2, EGFR, COX-2 expression status correlated to microvessel density and survival in resected non-small cell lung cancer. Brattström D; Wester K; Bergqvist M; Hesselius P; Malmström PU; Nordgren H; Wagenius G; Brodin O Acta Oncol; 2004; 43(1):80-6. PubMed ID: 15068324 [TBL] [Abstract][Full Text] [Related]
5. Development of a chemoresistant orthotopic human nonsmall cell lung carcinoma model in nude mice: analyses of tumor heterogenity in relation to the immunohistochemical levels of expression of cyclooxygenase-2, ornithine decarboxylase, lung-related resistance protein, prostaglandin E synthetase, and glutathione-S-transferase-alpha (GST)-alpha, GST-mu, and GST-pi. Mathieu A; Remmelink M; D'Haene N; Penant S; Gaussin JF; Van Ginckel R; Darro F; Kiss R; Salmon I Cancer; 2004 Oct; 101(8):1908-18. PubMed ID: 15386340 [TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors. Ermert L; Dierkes C; Ermert M Clin Cancer Res; 2003 May; 9(5):1604-10. PubMed ID: 12738712 [TBL] [Abstract][Full Text] [Related]
7. Cyclooxygenase-2 protein levels are independent of epidermal growth factor receptor expression or activation in operable non-small cell lung cancer. Richardson CM; Richardson D; Swinson DE; Swain WA; Cox G; O'Byrne KJ Lung Cancer; 2005 Apr; 48(1):47-57. PubMed ID: 15777970 [TBL] [Abstract][Full Text] [Related]
9. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Khuri FR; Wu H; Lee JJ; Kemp BL; Lotan R; Lippman SM; Feng L; Hong WK; Xu XC Clin Cancer Res; 2001 Apr; 7(4):861-7. PubMed ID: 11309334 [TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer. Krysan K; Dalwadi H; Sharma S; Põld M; Dubinett S Cancer Res; 2004 Sep; 64(18):6359-62. PubMed ID: 15374938 [TBL] [Abstract][Full Text] [Related]
11. Cyclooxygenase as a target in lung cancer. Brown JR; DuBois RN Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4266s-4269s. PubMed ID: 15217972 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of the whole prostaglandin biosynthetic pathway in lung cancer. DuBois RN Clin Cancer Res; 2003 May; 9(5):1577-8. PubMed ID: 12738708 [No Abstract] [Full Text] [Related]
13. Combination of a COX-2 inhibitor with radiotherapy or radiochemotherapy in the treatment of thoracic cancer. Liao Z; Milas L; Komaki R; Stevens C; Cox JD Am J Clin Oncol; 2003 Aug; 26(4):S85-91. PubMed ID: 12902863 [TBL] [Abstract][Full Text] [Related]
14. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. Liu X; Yue P; Zhou Z; Khuri FR; Sun SY J Natl Cancer Inst; 2004 Dec; 96(23):1769-80. PubMed ID: 15572759 [TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Coffey RJ; Hawkey CJ; Damstrup L; Graves-Deal R; Daniel VC; Dempsey PJ; Chinery R; Kirkland SC; DuBois RN; Jetton TL; Morrow JD Proc Natl Acad Sci U S A; 1997 Jan; 94(2):657-62. PubMed ID: 9012840 [TBL] [Abstract][Full Text] [Related]
16. Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor. Harichand-Herdt S; Ramalingam SS Semin Thorac Cardiovasc Surg; 2008; 20(3):217-23. PubMed ID: 19038731 [TBL] [Abstract][Full Text] [Related]
17. Interleukin-1beta-induced mucin production in human airway epithelium is mediated by cyclooxygenase-2, prostaglandin E2 receptors, and cyclic AMP-protein kinase A signaling. Gray T; Nettesheim P; Loftin C; Koo JS; Bonner J; Peddada S; Langenbach R Mol Pharmacol; 2004 Aug; 66(2):337-46. PubMed ID: 15266025 [TBL] [Abstract][Full Text] [Related]
18. Combining anti-Epidermal Growth Factor Receptor (EGFR) and anti-angiogenic strategies in advanced NSCLC: we should have known better…. Di Maio M; Morabito A; Piccirillo MC; Daniele G; Giordano P; Costanzo R; Sandomenico C; Montanino A; Rocco G; Perrone F Curr Pharm Des; 2014; 20(24):3901-13. PubMed ID: 24191956 [TBL] [Abstract][Full Text] [Related]
19. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Huang M; Stolina M; Sharma S; Mao JT; Zhu L; Miller PW; Wollman J; Herschman H; Dubinett SM Cancer Res; 1998 Mar; 58(6):1208-16. PubMed ID: 9515807 [TBL] [Abstract][Full Text] [Related]
20. Induction of cyclo-oxygenase-2 by cytokines in human cultured airway smooth muscle cells: novel inflammatory role of this cell type. Belvisi MG; Saunders MA; Haddad el-B ; Hirst SJ; Yacoub MH; Barnes PJ; Mitchell JA Br J Pharmacol; 1997 Mar; 120(5):910-6. PubMed ID: 9138698 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]